The past 18 months have been absolutely terrible for Novo Nordisk (NYSE: NVO). The Denmark-based drugmaker has faced poor ...

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

Danish Novo Nordisk launched its blockbuster treatment injection Ozempic in three forms in 0.25 mg, 0.5 mg and 1 mg in the ...

Inflammation likely plays a key role in T2D outcomes, and various anti-inflammatory treatments may improve both T2D and its ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...

Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...

MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...

Recent clinical research indicates that semaglutide may effectively reverse weight gain and blood sugar issues caused by ...

A new WHO guideline on GLP-1s and recent efforts to reduce the drugs’ costs now and going forward are unlikely to change US ...

Loss of muscle mass, also called muscle wasting or atrophy, can happen gradually as part of getting older or more suddenly ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...